Biotech Values

[dangerM]

Formulary decisions driving ViekiraPak higher claims rejections during its short time on the market. (/unquote)

http://symphonyhealth.com/wp-content/uploads/2015/03/Hep-C-Payer-Dynamics-Article.pdf

I think the rejection rates over time are highly interesting. If Vpak comes down from about 80% rejection rate to a 40-50% rejection rate as other treatments, this should have an effect even without better marketing/broader acceptance.


(I hope this link has not already been posted, I haven't seen this info yet - it is from 11.03.2015)